Company: AEMD
Filing Date: 2025-08-29
Form Type: S-1/A
Source: 0001683168-25-006537
Chunk: 52

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-29
Form: S-1/A
Chunk 52
---
 payable by us, our as adjusted net tangible book value as of June 30, 2025 would have been approximately $12,613,100 million,
or approximately $1.76 per share. This represents an immediate increase in net tangible book value of $0.44 per share to existing
stockholders and an immediate dilution of $0.43 per share to new investors purchasing shares of our common stock and accompanying
warrants in this offering, attributing none of the assumed combined public offering price to the warrants offered hereby. The following
table illustrates this per share dilution:

| Assumed                                                           
 combined public offering price per share and accompanying warrant |     |   |      |     | $ | 2.19 |
| Net tangible book value per share as of June 30,                  
 2025                                                              |     | $ | 1.32 |     |   |      |
| Increase in net tangible book value per share after               
 this offering                                                     |     |   | 0.44 |     |   |      |
| As adjusted net tangible                                          
 book value per share after this offering                          |     |   |      |     | $ | 1.76 |
| Dilution per share to new investors                               |     |   |      |     |   |      |
|                                                                   |     |   |      |     | $ | 0.43 |

A $0.10 increase in the assumed
combined public offering price of $2.19 per share and accompanying warrant (the last reported sale price of our common stock
on The Nasdaq Capital Market on August 21, 2025) would result in an increase in our as adjusted net tangible book value after
this offering of approximately $433,000, or approximately $0.06 per share, and the dilution per share to investors purchasing
common stock and accompanying warrants in this offering would be approximately $0.47 per share, assuming that the number of shares
of our common stock and accompanying warrants sold by us remains the same, after deducting the placement agent fees and estimated offering
expenses payable by us. Similarly, a decrease of $0.10 in the assumed combined public offering price of $2.19 per share and
accompanying warrant would result in a decrease in our as adjusted net tangible book value after this offering of approximately $433,000,
or approximately $0.06 per share, and the dilution per share to investors purchasing common stock and accompanying warrants in this
off